| Code | CSB-RA007779MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to LY-3848575, designed to specifically target epiregulin (EREG), a member of the epidermal growth factor (EGF) family. EREG functions as a ligand for the epidermal growth factor receptor (EGFR), playing critical roles in cell proliferation, differentiation, and tissue repair processes. Through its interaction with EGFR and ErbB4 receptors, epiregulin mediates multiple signaling pathways involved in wound healing, inflammation, and epithelial cell growth. Dysregulated EREG expression has been implicated in various pathological conditions, including cancer progression, metastasis, and therapeutic resistance, particularly in colorectal, lung, and breast cancers where it contributes to tumor growth and angiogenesis.
LY-3848575 represents a therapeutic antibody developed to inhibit EREG-mediated signaling pathways. This biosimilar antibody serves as a valuable research tool for investigating epiregulin biology, exploring EGFR pathway modulation, studying tumor microenvironment interactions, and evaluating potential therapeutic strategies targeting the EGF family network. It enables researchers to examine the role of EREG in disease models and advance understanding of growth factor-dependent cellular mechanisms.
There are currently no reviews for this product.